GlassScriptPhysician profile
Amanda Amy Dunec
NPI 1417229683
$4,763.28
in general payments reported to CMS, 2019-2025
30 companies · $897 in 2025
The $897 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $338 · 2021: $639 · 2022: $1,283 · 2023: $601 · 2024: $592 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.33 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,120.42 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $831.42 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $390.39 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Pfizer INC. | $278.02 | 2019-2025 | |
| Amgen INC. | $231.11 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $230.17 | 2019-2025 | Blu-U, Odomzo |
| Genzyme Corporation | $209.40 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $164.70 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Incyte Corporation | $161.84 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $151.72 | 2019-2025 | |
| Galderma Laboratories, L.P. | $145.94 | 2020-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $145.68 | 2019-2025 | Libtayo |
| Mayne Pharma Commercial LLC | $116.76 | 2019-2025 | |
| Ucb, INC. | $82.08 | 2021-2025 | Bimzelx |
| Allergan, INC. | $73.48 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $59.82 | 2020-2025 | Anzupgo |
| Biofrontera INC. | $55.21 | 2019-2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Journey Medical Corporation | $43.28 | 2020-2023 | |
| Strata Skin Sciences, INC. | $38.92 | 2024-2025 | Xtrac |
| Botanix Sb INC | $35.26 | 2025 | Sofdra |
| Almirall LLC | $31.21 | 2019-2025 | Klisyri |
| Vyne Pharmaceuticals INC. | $29.90 | 2020 | |
| Dermira, INC. | $29.48 | 2019-2020 | |
| Dermavant Sciences, INC. | $18.00 | 2024 | Vtama |
| Convatec INC. | $16.12 | 2025 | |
| Arcutis Biotherapeutics, INC. | $15.70 | 2024 | Zoryve |
| Mission Pharmacal Company | $15.02 | 2021 | |
| Nabriva Therapeutics, Plc | $15.00 | 2022 | |
| Verrica Pharmaceuticals INC. | $13.99 | 2023 | Ycanth |
| Celgene Corporation | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Dunec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.